2019年冠状病毒病大流行对慢性炎症性免疫介导性皮肤病病程及管理的影响：有哪些证据？
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
作者信息
Patsatsi Aikaterini, Kyriakou Aikaterini
机构信息
2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
2nd Department of Dermatology, Aristotle University School of Medicine, Papageorgiou General Hospital, Thessaloniki, Greece.
出版信息
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
Abstract
Since the beginning of the coronavirus disease 2019 (COVID-19) pandemic, medical professionals have been overwhelmed by questions beyond the infection itself. In dermatology practice, clinicians have been facing difficulties about the management of chronic immune-mediated skin diseases. Issues arose, such as the grade of immunosuppression or immunomodulation, discontinuation or modification of treatment, and initiation of new treatments. In this comprehensive review, we present the current evidence about the course and management of chronic inflammatory dermatoses during the COVID-19 pandemic, focusing on psoriasis, atopic dermatitis, and hidradenitis suppurativa.
摘要
自2019冠状病毒病（COVID-19）大流行开始以来，医学专业人员被感染本身之外的问题压得喘不过气来。在皮肤科实践中，临床医生在慢性免疫介导性皮肤病的管理方面一直面临困难。出现了一些问题，如免疫抑制或免疫调节的程度、治疗的中断或调整以及新治疗方法的启动。在这篇综述中，我们介绍了COVID-19大流行期间慢性炎症性皮肤病的病程和管理的当前证据，重点关注银屑病、特应性皮炎和化脓性汗腺炎。
相似文献
1
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence?
Clin Dermatol. 2021 Jan-Feb;39(1):52-55. doi: 10.1016/j.clindermatol.2020.12.012. Epub 2020 Dec 15.
2
Biologic drugs during COVID-19 outbreak.
Int J Dermatol. 2020 Oct;59(10):1293. doi: 10.1111/ijd.15088. Epub 2020 Aug 6.
3
Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic.
Dermatol Online J. 2020 Oct 15;26(10):13030/qt0j5150df.
4
A Practical Guide to Using Biologics in Pediatric Dermatology.
J Cutan Med Surg. 2024 Jan-Feb;28(1):59-67. doi: 10.1177/12034754231222415. Epub 2024 Jan 16.
5
[Impact of the COVID-19 Pandemic on Immunomodulatory and Immunosuppressive Therapies in Dermatology: Patient and Physician Attitudes in Argentina].
Actas Dermosifiliogr (Engl Ed). 2020 Nov;111(9):806-807. doi: 10.1016/j.ad.2020.04.004. Epub 2020 Apr 29.
6
Immunobiologicals in dermatology.
An Bras Dermatol. 2022 May-Jun;97(3):275-283. doi: 10.1016/j.abd.2021.05.016. Epub 2022 Mar 18.
7
[What's New in Dermatological Therapy?].
Ann Dermatol Venereol. 2015 Dec;142 Suppl 3:S49-54. doi: 10.1016/S0151-9638(16)30006-0.
8
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy.
Dermatol Ther. 2020 Nov;33(6):e14256. doi: 10.1111/dth.14256. Epub 2020 Sep 14.
9
No impact of immunomodulatory treatments on SARS-CoV-2 (COVID-19) vaccine outcomes: A cross-sectional analysis of biologic and small molecule inhibitors used for psoriasis and hidradenitis suppurativa patients from the Epic Cosmos database.
J Am Acad Dermatol. 2024 Jul;91(1):100-102. doi: 10.1016/j.jaad.2024.03.004. Epub 2024 Mar 13.
10
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment?
J Dermatolog Treat. 2022 Feb;33(1):599. doi: 10.1080/09546634.2020.1771256. Epub 2020 Jun 19.
引用本文的文献
1
Treatment Adherence in Dermatology During the COVID-19 Pandemic: A Review.
Cureus. 2023 Jan 24;15(1):e34141. doi: 10.7759/cureus.34141. eCollection 2023 Jan.
2
Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data.
Immunol Res. 2023 Jun;71(3):328-355. doi: 10.1007/s12026-022-09356-y. Epub 2023 Jan 4.
3
A cross-sectional study of dermatologists' attitudes towards COVID-19 vaccination in patients with immunobullous diseases.
J Eur Acad Dermatol Venereol. 2023 Feb;37(2):e132-e134. doi: 10.1111/jdv.18674. Epub 2022 Oct 29.
4
Development of Approaches and Metrics to Measure the Impact and Improve the Clinical Outcomes of Patients With Frailty in the Era of COVID-19. The COMETA Italian Protocol.
Front Oncol. 2022 Jun 2;12:828660. doi: 10.3389/fonc.2022.828660. eCollection 2022.
5
The overall impact of COVID-19 on healthcare during the pandemic: A multidisciplinary point of view.
Health Sci Rep. 2021 Oct 1;4(4):e386. doi: 10.1002/hsr2.386. eCollection 2021 Dec.
6
Dermatological manifestations associated with COVID-19: A comprehensive review of the current knowledge.
J Med Virol. 2021 Oct;93(10):5756-5767. doi: 10.1002/jmv.27187. Epub 2021 Jul 16.
本文引用的文献
1
Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19.
J Eur Acad Dermatol Venereol. 2020 Nov;34(11):e676-e679. doi: 10.1111/jdv.16761. Epub 2020 Jul 9.
2
Management of adult patients with severe atopic dermatitis treated with dupilumab during COVID-19 pandemic: A single-center real-life experience.
Dermatol Ther. 2020 Jul;33(4):e13765. doi: 10.1111/dth.13765. Epub 2020 Jun 30.
3
Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak.
Dermatol Ther. 2020 Jul;33(4):e13680. doi: 10.1111/dth.13680. Epub 2020 Jun 18.
4
Patient-Driven Discontinuation of Dupilumab During the COVID-19 Pandemic in Two Academic Hospital Clinics at the University of Toronto.
J Cutan Med Surg. 2020 Jul/Aug;24(4):422-423. doi: 10.1177/1203475420930223. Epub 2020 May 20.
5
Comment on "Antipsoriatic treatments during COVID-19 outbreak".
Dermatol Ther. 2020 Jul;33(4):e13491. doi: 10.1111/dth.13491. Epub 2020 Jun 12.
6
SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor.
J Eur Acad Dermatol Venereol. 2020 Aug;34(8):e357-e358. doi: 10.1111/jdv.16571. Epub 2020 Jun 8.
7
Biologics increase the risk of SARS-CoV-2 infection and hospitalization, but not ICU admission and death: Real-life data from a large cohort during red-zone declaration.
Dermatol Ther. 2020 Sep;33(5):e13475. doi: 10.1111/dth.13475. Epub 2020 May 19.
8
Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic.
Br J Dermatol. 2020 Aug;183(2):404-406. doi: 10.1111/bjd.19161. Epub 2020 Jun 10.
9
The impact of the COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience.
Br J Dermatol. 2020 Aug;183(2):373-374. doi: 10.1111/bjd.19158. Epub 2020 May 28.
10
Reply: Potential role of Janus kinase inhibitors in COVID-19.
J Am Acad Dermatol. 2020 Jul;83(1):e65. doi: 10.1016/j.jaad.2020.04.098. Epub 2020 Apr 24.
Zotero 插件